Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
Virginia Mason Medical Center
mi
from
Seattle, WA
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
Univ of Washington
mi
from
Seattle, WA
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
Providence Sacred Heart Medical Center
mi
from
Spokane, WA
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
Providence Sacred Heart Medical Center
mi
from
Spokane, WA
Click here to add this to my saved trials
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
Henry Ford Health System
mi
from
Detroit, MI
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
Weill Cornell Medical Center
mi
from
New York, NY
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
SUNY Upstate Medical University
mi
from
Syracuse, NY
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
University of Texas Southwestern
mi
from
Dallas, TX
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
University of Calgary
mi
from
Calgary,
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
Washington University
mi
from
Saint Louis, MO
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated:  3/7/2018
Gunderson Health System
mi
from
La Crosse, WI
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Status: Enrolling
Updated: 3/7/2018
Gunderson Health System
mi
from
La Crosse, WI
Click here to add this to my saved trials
Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury
Status: Enrolling
Updated:  3/7/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury
Status: Enrolling
Updated: 3/7/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated:  3/8/2018
UCLA Medical Center
mi
from
Los Angeles, CA
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated: 3/8/2018
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated:  3/8/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated: 3/8/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated:  3/8/2018
Cleveland Clinic
mi
from
Cleveland, OH
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated: 3/8/2018
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated:  3/8/2018
University of Virginia - Nephrology Clinical Research Center
mi
from
Charlottesville, VA
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated: 3/8/2018
University of Virginia - Nephrology Clinical Research Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated:  3/8/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated: 3/8/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated:  3/8/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated: 3/8/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Tacrolimus to Sirolimus Conversion for Delayed Graft Function
Delayed Tacrolimus to Sirolimus Conversion in Renal Transplant Recipients With Delayed Graft Function
Status: Enrolling
Updated:  3/13/2018
University of Maryland Medical Center
mi
from
Baltimore, MD
Tacrolimus to Sirolimus Conversion for Delayed Graft Function
Delayed Tacrolimus to Sirolimus Conversion in Renal Transplant Recipients With Delayed Graft Function
Status: Enrolling
Updated: 3/13/2018
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Impact of Neuromonitoring During Cardiac Procedures
Impact of Neuromonitoring During Cardiothoracic Procedures: A Retrospective Analysis
Status: Enrolling
Updated:  3/13/2018
Vanderbilt University School of Medicine
mi
from
Nashville, TN
Impact of Neuromonitoring During Cardiac Procedures
Impact of Neuromonitoring During Cardiothoracic Procedures: A Retrospective Analysis
Status: Enrolling
Updated: 3/13/2018
Vanderbilt University School of Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS- 986177 in Participants With Normal Renal Function and Participants With Moderate and Severe Renal Impairment
Status: Enrolling
Updated:  3/13/2018
Clinical Pharmacology of Miami
mi
from
Miami, FL
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS- 986177 in Participants With Normal Renal Function and Participants With Moderate and Severe Renal Impairment
Status: Enrolling
Updated: 3/13/2018
Clinical Pharmacology of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure
Status: Enrolling
Updated:  3/14/2018
Massachusetts General Hospital
mi
from
Boston, MA
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure
Status: Enrolling
Updated: 3/14/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease
Targeting the Interactions Between Disordered Iron Homeostasis and Mineral Metabolism in Chronic Kidney Disease (Aim 1)
Status: Enrolling
Updated:  3/14/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease
Targeting the Interactions Between Disordered Iron Homeostasis and Mineral Metabolism in Chronic Kidney Disease (Aim 1)
Status: Enrolling
Updated: 3/14/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant
Status: Enrolling
Updated:  3/15/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant
Status: Enrolling
Updated: 3/15/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
Status: Enrolling
Updated:  3/16/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
Status: Enrolling
Updated: 3/16/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients
Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients
Status: Enrolling
Updated:  3/17/2018
Northwestern Memorial Hospital
mi
from
Chicago, IL
Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients
Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients
Status: Enrolling
Updated: 3/17/2018
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
Status: Enrolling
Updated:  3/17/2018
Midwestern University/Northwestern Memorial Hospital
mi
from
Chicago, IL
Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
Status: Enrolling
Updated: 3/17/2018
Midwestern University/Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)
Renal Transplantation Followed By Infusion of T-Regulatory Cells Made With Belatacept Ex-Vivo
Status: Enrolling
Updated:  3/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)
Renal Transplantation Followed By Infusion of T-Regulatory Cells Made With Belatacept Ex-Vivo
Status: Enrolling
Updated: 3/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
DIVINE: Dialysis Infection and Vitamin D In New England
DIVINE: Dialysis Infection and Vitamin D In New England
Status: Enrolling
Updated:  3/21/2018
Massachusetts General Hospital
mi
from
Boston, MA
DIVINE: Dialysis Infection and Vitamin D In New England
DIVINE: Dialysis Infection and Vitamin D In New England
Status: Enrolling
Updated: 3/21/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
DIVINE: Dialysis Infection and Vitamin D In New England
DIVINE: Dialysis Infection and Vitamin D In New England
Status: Enrolling
Updated:  3/21/2018
Brigham and Women's Hosp
mi
from
Boston, MA
DIVINE: Dialysis Infection and Vitamin D In New England
DIVINE: Dialysis Infection and Vitamin D In New England
Status: Enrolling
Updated: 3/21/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
DIVINE: Dialysis Infection and Vitamin D In New England
DIVINE: Dialysis Infection and Vitamin D In New England
Status: Enrolling
Updated:  3/21/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
DIVINE: Dialysis Infection and Vitamin D In New England
DIVINE: Dialysis Infection and Vitamin D In New England
Status: Enrolling
Updated: 3/21/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Vitamin D Replacement After Kidney Transplant
Vitamin D Replacement After Kidney Transplant
Status: Enrolling
Updated:  3/21/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Vitamin D Replacement After Kidney Transplant
Vitamin D Replacement After Kidney Transplant
Status: Enrolling
Updated: 3/21/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Transplant Navigator Dissemination
Status: Enrolling
Updated:  3/21/2018
Lutheran Hospital
mi
from
Fort Wayne, IN
Transplant Navigator Dissemination
Status: Enrolling
Updated: 3/21/2018
Lutheran Hospital
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Transplant Navigator Dissemination
Status: Enrolling
Updated:  3/21/2018
University of Kentucky
mi
from
Lexington, KY
Transplant Navigator Dissemination
Status: Enrolling
Updated: 3/21/2018
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Transplant Navigator Dissemination
Status: Enrolling
Updated:  3/21/2018
Jewish Hospital
mi
from
Louisville, KY
Transplant Navigator Dissemination
Status: Enrolling
Updated: 3/21/2018
Jewish Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Transplant Navigator Dissemination
Status: Enrolling
Updated:  3/21/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Transplant Navigator Dissemination
Status: Enrolling
Updated: 3/21/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Transplant Navigator Dissemination
Status: Enrolling
Updated:  3/21/2018
Ohio State University
mi
from
Columbus, OH
Transplant Navigator Dissemination
Status: Enrolling
Updated: 3/21/2018
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients
Global Multicentre Kidney Transplant Advagraf Conversion Registry. A Non-interventional Post-authorisation Study (PAS)
Status: Enrolling
Updated:  3/21/2018
Site US10013
mi
from
Chicago, IL
Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients
Global Multicentre Kidney Transplant Advagraf Conversion Registry. A Non-interventional Post-authorisation Study (PAS)
Status: Enrolling
Updated: 3/21/2018
Site US10013
mi
from
Chicago, IL
Click here to add this to my saved trials
Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients
Global Multicentre Kidney Transplant Advagraf Conversion Registry. A Non-interventional Post-authorisation Study (PAS)
Status: Enrolling
Updated:  3/21/2018
Site AU6107
mi
from
Camperdown,
Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients
Global Multicentre Kidney Transplant Advagraf Conversion Registry. A Non-interventional Post-authorisation Study (PAS)
Status: Enrolling
Updated: 3/21/2018
Site AU6107
mi
from
Camperdown,
Click here to add this to my saved trials
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
A Randomized, Placebo-Controlled Double-Blind Trial Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation: A Pilot Study
Status: Enrolling
Updated:  3/22/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
A Randomized, Placebo-Controlled Double-Blind Trial Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation: A Pilot Study
Status: Enrolling
Updated: 3/22/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
Randomized Conversion of Calcineurin-Inhibitors(Tacrolimus to Sirolimus),6-24 Months Post Transplant Prednisone-Free Immunosuppression Regimen: Impact of Incidence of Acute Cellular Rejection,Renal Allograft Function & Lymphocytes Function
Status: Enrolling
Updated:  3/27/2018
Northwestern Memorial Hospital
mi
from
Chicago, IL
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
Randomized Conversion of Calcineurin-Inhibitors(Tacrolimus to Sirolimus),6-24 Months Post Transplant Prednisone-Free Immunosuppression Regimen: Impact of Incidence of Acute Cellular Rejection,Renal Allograft Function & Lymphocytes Function
Status: Enrolling
Updated: 3/27/2018
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
Extended Arm Physician, Inc.
mi
from
Montgomery, AL
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
Extended Arm Physician, Inc.
mi
from
Montgomery, AL
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
North American Research Institute
mi
from
Azusa, CA
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
North American Research Institute
mi
from
Azusa, CA
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
Renal Consultants Medical Group
mi
from
Granada Hills, CA
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
Renal Consultants Medical Group
mi
from
Granada Hills, CA
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
Marin Endocrine Associates
mi
from
Greenbrae, CA
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
Marin Endocrine Associates
mi
from
Greenbrae, CA
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
Academic Medical Research Institute
mi
from
Los Angeles, CA
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
Academic Medical Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
Sutter Gould Medical Foundation
mi
from
Modesto, CA
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
Sutter Gould Medical Foundation
mi
from
Modesto, CA
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
Infosphere
mi
from
West Hills, CA
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
Infosphere
mi
from
West Hills, CA
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
Chase Medical Research, LLC
mi
from
Waterbury, CT
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
Chase Medical Research, LLC
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
The Center for Diabetes and Endocrine Care
mi
from
Hollywood, FL
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
The Center for Diabetes and Endocrine Care
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated:  3/27/2018
East Coast Clinical Research
mi
from
Jacksonville, FL
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status: Enrolling
Updated: 3/27/2018
East Coast Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials